A new study led by researchers from The University of Texas MD Anderson Cancer Center has shed some light on the matter of predicting when immunotherapies will work in cancer.
The study shows that a high rate of genetic mutations within a tumor, known as high tumor mutation burden (TMB), is only useful for predicting clinical responses to immune checkpoint inhibitors in a subset of cancer types.
"Our results do not support applying high TMB status as a universal biomarker for immunotherapy response"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze